title: Inhibition of ovarian cancer growth and implantation by paclitaxel after laparoscopic surgery in a mouse model.
abstract: OBJECTIVE
  We used an established experimental model to evaluate the influence of intraperitoneal chemotherapy on the generation of laparoscopy-associated metastases and the effectiveness of chemotherapy.
  
  
  METHODS
  Twenty-four nude mice underwent laparoscopy with carbon dioxide insufflation and the instillation of a tumor cell suspension with or without paclitaxel into the peritoneal cavity. Mice were allocated to 1 of the following groups (8 mice to each group): (1) controls; (2) paclitaxel given during the operation; (3) paclitaxel given after the operation. Mice were killed 30 days after the procedure, and the peritoneal cavity and port sites were examined for the presence of tumors.
  
  
  RESULTS
  Tumor implantation and port-site metastases were reduced more by the intraoperative intraperitoneal administration of paclitaxel during the operation than by administration after the operation.
  
  
  CONCLUSIONS
  Intraoperative intraperitoneal administration of paclitaxel may decrease significantly the occurrence of port-site metastasis and intraperitoneal dissemination in an animal study.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Gynecologic Endoscopy, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan. chyilong@ms21.hinet.net
authors.forename: Chyi-Long
authors.initials: CL
authors.lastname: Lee
authors.forename: Nari
authors.initials: N
authors.lastname: Kay
mesh_terms: D000005:Abdomen / Q000601:surgery*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology*; D045744:Cell Line, Tumor; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007432:Intraoperative Period; D010535:Laparoscopy / Q000009:adverse effects*; D051379:Mice; D008819:Mice, Nude; D009366:Neoplasm Seeding; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000556:secondary*; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology*; D011184:Postoperative Period
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel